UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Clinical cancer research, 2016-12, Vol.22 (23), p.5829-5838

2016

Volltextzugriff (PDF)

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

Haematologica (Roma), 2022-01, Vol.107 (1), p.292-297

2022

Volltextzugriff (PDF)

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

The lancet oncology, 2015-09, Vol.16 (9), p.1025-1036

2015

Volltextzugriff (PDF)

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Haematologica (Roma), 2022-04, Vol.107 (4), p.984-987

2022

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Journal of clinical oncology, 2010-06, Vol.28 (18), p.3015-3022

2010

Volltextzugriff (PDF)

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

Blood, 2009-05, Vol.113 (19), p.4637-4645

2009

Volltextzugriff (PDF)

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

PloS one, 2010-04, Vol.5 (4), p.e10186

2010

Volltextzugriff (PDF)

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-04, Vol.14 (7), p.2075-2081

2008

Volltextzugriff (PDF)

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Haematologica (Roma), 2015-02, Vol.100 (2), p.231-237

2015

Volltextzugriff (PDF)

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Haematologica (Roma), 2018-11, Vol.103 (11), p.e514-e518

2018

Volltextzugriff (PDF)

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

Nature medicine, 2001-04, Vol.7 (4), p.383-385

2001

Volltextzugriff (PDF)

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Clinical cancer research, 2010-04, Vol.16 (7), p.2167-2175

2010

Volltextzugriff (PDF)

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma

Molecular therapy, 2022-06, Vol.30 (6), p.2315-2326

2022

Volltextzugriff (PDF)

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Blood, 2022-02, Vol.139 (6), p.859-875

2022

Volltextzugriff (PDF)

Characterization of Humanized Antibodies Secreted by Aspergillus niger

Applied and Environmental Microbiology, 2004-05, Vol.70 (5), p.2567-2576

2004

Volltextzugriff (PDF)

Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia

Drugs (New York, N.Y.), 2016-09, Vol.76 (13), p.1245-1255

2016

Volltextzugriff (PDF)

Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin

Dalton transactions : an international journal of inorganic chemistry, 2015-02, Vol.44 (5), p.2348-2358

2015

Volltextzugriff (PDF)

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

Cancer chemotherapy and pharmacology, 2009-09, Vol.64 (4), p.723-732

2009

Volltextzugriff (PDF)

Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice

Drug metabolism and disposition, 2005-05, Vol.33 (5), p.623-629

2005

Volltextzugriff (PDF)

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models

Oncotarget, 2017-05, Vol.8 (18), p.29865-29886

2017

Volltextzugriff (PDF)

REVEAL‐1, a phase 2 dose regimen optimization study of vosaroxin in older poor‐risk patients with previously untreated acute myeloid leukaemia

British journal of haematology, 2015-03, Vol.168 (6), p.796-805

2015

Volltextzugriff (PDF)

Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety

The Journal of pharmacology and experimental therapeutics, 2001-10, Vol.299 (1), p.31

2001

Volltextzugriff (PDF)

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

Cancer chemotherapy and pharmacology, 2010-10, Vol.66 (5), p.881-888

2010

Volltextzugriff (PDF)

Insulin-Stimulated Hydrolysis of a Novel Glycolipid Generates Modulators of cAMP Phosphodiesterase

Science (American Association for the Advancement of Science), 1986-08, Vol.233 (4767), p.967-972

1986

Volltextzugriff (PDF)

Characterization of a CC49-Based Single-Chain Fragment−β-Lactamase Fusion Protein for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

Bioconjugate chemistry, 2006-03, Vol.17 (2), p.410-418

2006

Volltextzugriff (PDF)

1 – 25 von 865

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(658)
Mit Volltextzugriff
(692)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Governance Directions
(68)
Blood
(21)
Keeping Good Companies
(19)
Neurology
(18)
Circulation
(13)
Plos One
(13)
The American Journal Of Psychoanalysis
(11)
Chemical Communications
(10)
Dalton Transactions : An International Journal Of Inorganic Chemistry
(10)
Strategies
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Characterization of Humanized Antibodies Secreted by Aspergillus niger

Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia

Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models

REVEAL‐1, a phase 2 dose regimen optimization study of vosaroxin in older poor‐risk patients with previously untreated acute myeloid leukaemia

Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

Insulin-Stimulated Hydrolysis of a Novel Glycolipid Generates Modulators of cAMP Phosphodiesterase

Characterization of a CC49-Based Single-Chain Fragment−β-Lactamase Fusion Protein for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

Suchergebnisse filtern